# OnCo record da-lecanemab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/da-lecanemab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "da-lecanemab" ;
  schema:name "Lecanemab"@en ;
  schema:description "Lecanemab is an infused antibody for early Alzheimer’s disease after amyloid is confirmed. It can cause brain swelling or bleeding on MRI and is not a cure."@en ;
  schema:url <https://onco.cc/drugs/da-lecanemab/> ;
  schema:dateModified "2026-09-21"^^xsd:date ;
  schema:citation <https://www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-treatment-traditional-approval> ;
  onco:status "approved" ;
  onco:tag "dementia-atlas" ;
  onco:modality "mAb" ;
  schema:alternateName "Leqembi" ;
  onco:approval "US 2023: Early Alzheimer’s disease with confirmed amyloid", "JP 2023: Early Alzheimer’s disease", "CN 2024: Early Alzheimer’s disease", "UK 2024: Licensed; funding decisions are separate from the licence", "EU 2025: Authorisation pathway; national access varies", "AU 2025: Regulatory review or access may lag the US label" ;
  onco:cancers <https://onco.cc/diagnoses/alzheimers-disease/>, <https://onco.cc/diagnoses/mild-cognitive-impairment/> ;
  onco:targets <https://onco.cc/targets/da-target-amyloid-beta/> ;
  onco:companies <https://onco.cc/companies/da-eisai/>, <https://onco.cc/companies/da-biogen/> ;
  onco:terms <https://onco.cc/terms/da-term-aria/> ;
  onco:trials <https://onco.cc/trials/da-trial-clarity-ad/> .